Quest Diagnostics

Quest Diagnostics is an independent provider of diagnostic information services with a national presence. The company was founded in 1967, originally known as Metropolitan Pathology Laboratory, and has grown steadily over the decades through a combination of organic expansion and strategic acquisitions. One notable milestone in its history was the acquisition of AmeriPath, which helped broaden its specialty testing capabilities and strengthen its market reach.

As of November 2025, Quest Diagnostics operates more than 2,200 patient service centers across all 50 states, supported by a network of regional laboratories. Over the past five years, Quest has focused on expanding in high-growth urban and suburban markets, with particular emphasis on states like California, Texas, Florida, New York, Illinois, and Georgia. The company has also invested in new patient service centers and regional labs, reflecting its commitment to increasing accessibility and meeting rising demand for diagnostic testing.

Quest’s service offerings include routine and advanced clinical testing, genetic and molecular diagnostics, and risk assessment services for the life insurance industry. In recent years, the company has evolved by integrating digital health solutions, collaborating with wearable technology platforms and health data apps to make lab results and personalized health insights more accessible to patients and clinicians. These partnerships and technology investments have positioned Quest as a credible and flexible tenant, able to adapt to a variety of real estate formats including medical office, retail, and mixed-use developments.

With approximately 49,000 employees and third quarter 2025 revenues of $2.82 billion, Quest Diagnostics maintains a strong posture for growth. Its ongoing expansion, diversified service formats, and established reputation make it a significant operator in the healthcare and real estate landscape.